Antiarrhythmic drug initiation in patients with atrial fibrillation

The Influence of Gender on Arrhythmias

It is becoming increasingly apparent that there are important gender differences in normal cardiac physiology. These, in turn, could be associated with differences in the type and severity of cardiac arrhythmias. Women have higher resting heart rates than men, probably as a result of a combination of autonomic and intrinsic factors. The clinical significance of this observation is unclear at the present time. Women have a lower incidence of sudden cardiac death, which could be related to the delayed onset of coronary artery disease in women, presumably as a result of the protective effects of female hormones during gestational years. In survivors of sudden cardiac death, there are major gender differences, with fewer women having underlying coronary artery disease and a greater percentage of women having structurally normal hearts. QT interval prolongation and Torsade de Pointes are more common in women, probably on the basis of differences in ion channels between genders. Women appear especially susceptible to Torsades from QT-prolonging drugs such as quinidine or tricyclic antidepressant medications. The mechanisms of paroxysmal supraventricular tachycardia differ between the genders, although therapy seems to be equally efficacious in men and women. Lastly, atrial fibrillation is considerably more common in men. There is also some evidence that it is better tolerated by men.

Cost effectiveness of therapies for atrial fibrillation. A review

Atrial fibrillation is the most common supraventricular tachyarrhythmia encountered in clinical practice, affecting over 5% of persons over the age of 65 years. A common pathophysiological mechanism for arrhythmia development is atrial distention and fibrosis induced by hypertension, coronary artery disease or ventricular dysfunction. Less frequently, atrial fibrillation is caused by mitral stenosis or other provocative factors such as thyrotoxicosis, pericarditis or alcohol intoxication. Depending on the extent of associated cardiovascular disease, atrial fibrillation may produce haemodynamic compromise, or symptoms such as palpitations, fatigue, chest pain or dyspnoea. Arrhythmia-induced atrial stasis can precipitate clot formation and the potential for subsequent thromboembolism. Comprehensive management of atrial fibrillation requires a multifaceted approach directed at controlling symptoms, protecting the patient from ischaemic stroke or peripheral embolism and possible conversion to or maintenance of sinus rhythm. Numerous randomised trials have demonstrated the efficacy of warfarin--and less so aspirin (acetylsalicylic acid)--in reducing the risk of embolic events. Furthermore, therapeutic strategies exist that can favourably modify symptoms by restoring and maintaining sinus rhythm with cardioversion and antiarrhythmic prophylaxis. However, the risks and benefits of various treatments is highly dependent on patient-specific features, emphasising the need for an individualised approach. This article reviews the findings of cost-effectiveness studies published over the past decade that have evaluated different components of treatment strategies for atrial fibrillation. These studies demonstrate the economic attractiveness of acute management options, long term warfarin prophylaxis, telemetry-guided initiation of antiarrhythmic therapy, approaches to restore and maintain sinus rhythm, and the potential role of transoesophageal echocardiographic screening for atrial thrombus prior to pharmacological or electrical cardioversion. Further, we discuss the merits and limitations of the cost-effectiveness analyses in the context of overall treatment strategies. Finally, we identify areas that will require additional research to achieve the goal of effective and economically efficient management of atrial fibrillation.